---
figid: PMC4226664__oncotarget-05-8014-g001
figlink: /pmc/articles/PMC4226664/figure/F1/
number: F1
caption: IGF signalling occurs through stimulation of insulin-like growth factor 1
  receptors (IGF1R; shown in blue in the cell membrane) by IGF2 and results in activation
  of the PI3K and MAPK signalling pathways, an increase in protein synthesis, cell
  cycle progression, cell growth and avoiding apoptosis. Activation of the IGF pathway
  through overexpression of IGF2 is frequently seen in Wilms tumour (WT) and is therefore
  a viable therapeutic target. IGF pathway inhibitors include antisense oligonucleotides
  which target IGF1R mRNA (green) to prevent their translation into functional protein
  or molecules that target the IGF1R, which include AMG-479 in combination with Gemcitabine,
  BMS-754807, Figitumumab, IMC-A12 (alone or with Gemcitabine), NVP-AEW541 and R1507.
  As frequent epigenomic aberrations are also found in WT (see main text and Table
  ) targeting enzymes that regulate DNA methylation (DNA methyal transferases; DNMT)
  or that regulate histone modifications (histone deacetylases; HDAC) may be a viable
  therapy for patients with WT. In terms of targeting the epigenome, 5-azacytidine,
  5-aza-2'-deoxycytidine and Zebularine are DNMT inhibitors and Vorinostat and Romidepsin
  are both HDAC inhibitors, preventing normal enzymatic activity.
pmcid: PMC4226664
papertitle: The IGF signalling pathway in Wilms tumours - A report from the ENCCA
  Renal Tumours Biology-driven drug development workshop.
reftext: Mariana Maschietto, et al. Oncotarget. 2014 Sep;5(18):8014-8026.
pmc_ranked_result_index: '725'
pathway_score: 0.9483165
filename: oncotarget-05-8014-g001.jpg
figtitle: IGF signalling pathway in Wilms tumours - A report from the ENCCA Renal
  Tumours Biology-driven drug development workshop
year: '2014'
organisms:
- Homo sapiens
ndex: 85034040-dede-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4226664__oncotarget-05-8014-g001.html
  '@type': Dataset
  description: IGF signalling occurs through stimulation of insulin-like growth factor
    1 receptors (IGF1R; shown in blue in the cell membrane) by IGF2 and results in
    activation of the PI3K and MAPK signalling pathways, an increase in protein synthesis,
    cell cycle progression, cell growth and avoiding apoptosis. Activation of the
    IGF pathway through overexpression of IGF2 is frequently seen in Wilms tumour
    (WT) and is therefore a viable therapeutic target. IGF pathway inhibitors include
    antisense oligonucleotides which target IGF1R mRNA (green) to prevent their translation
    into functional protein or molecules that target the IGF1R, which include AMG-479
    in combination with Gemcitabine, BMS-754807, Figitumumab, IMC-A12 (alone or with
    Gemcitabine), NVP-AEW541 and R1507. As frequent epigenomic aberrations are also
    found in WT (see main text and Table ) targeting enzymes that regulate DNA methylation
    (DNA methyal transferases; DNMT) or that regulate histone modifications (histone
    deacetylases; HDAC) may be a viable therapy for patients with WT. In terms of
    targeting the epigenome, 5-azacytidine, 5-aza-2'-deoxycytidine and Zebularine
    are DNMT inhibitors and Vorinostat and Romidepsin are both HDAC inhibitors, preventing
    normal enzymatic activity.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HDAC4
  - SIRT2
  - HDAC9
  - HDAC3
  - HDAC5
  - DNMT1
  - SIRT5
  - HDAC2
  - HDAC11
  - HDAC10
  - HDAC7
  - HDAC8
  - PIK3R6
  - PIK3R5
  - PIK3R3
  - MAPK10
  - MAPK8
  - MAPK11
  - SIRT7
  - MAPK3
  - HDAC1
  - IGF1R
  - MAPK9
  - PIK3CG
  - PIK3CA
  - SIRT1
  - SIRT6
  - PIK3R4
  - SIRT4
  - PIK3CB
  - MAPK14
  - HDAC6
  - PIK3CD
  - SIRT3
  - MAPK12
  - IGF2
  - MAPK1
  - MAPK13
  - Zebularine
  - Gemcitabine
  - Romidepsin
  - BMS-754807
  - 5-azacytidine
genes:
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC4
  entrez: '9759'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT2
  entrez: '22933'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC9
  entrez: '9734'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC3
  entrez: '8841'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC5
  entrez: '10014'
- word: DNMT
  symbol: DNMT
  source: hgnc_prev_symbol
  hgnc_symbol: DNMT1
  entrez: '1786'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT5
  entrez: '23408'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC2
  entrez: '3066'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC11
  entrez: '79885'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC10
  entrez: '83933'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC7
  entrez: '51564'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC8
  entrez: '55869'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT7
  entrez: '51547'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC1
  entrez: '3065'
- word: IGF1R
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT1
  entrez: '23411'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT6
  entrez: '51548'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT4
  entrez: '23409'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC6
  entrez: '10013'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT3
  entrez: '23410'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: IGF2
  symbol: IGF2
  source: hgnc_symbol
  hgnc_symbol: IGF2
  entrez: '3481'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
chemicals:
- word: Zebularine
  source: MESH
  identifier: C009131
- word: Gemcitabine
  source: MESH
  identifier: C056507
- word: Romidepsin
  source: MESH
  identifier: C087123
- word: BMS-754807
  source: MESH
  identifier: C545990
- word: 5-azacytidine
  source: MESH
  identifier: D001374
diseases: []
figid_alias: PMC4226664__F1
redirect_from: /figures/PMC4226664__F1
figtype: Figure
---
